Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Conference on HIV Science (IAS 2025) concluded in Kigali after five dynamic days (July 13-17), delegates left with a mix of hope and concern--buoyed by scientific breakthroughs but unsettled by a ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by. Presented ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...